Skip to main content
. 2022 Feb 16;603(7899):152–158. doi: 10.1038/s41586-022-04419-4

Extended Data Table 1.

Clinical and demographic baseline characteristics of all study cohorts

graphic file with name 41586_2022_4419_Tab1_ESM.jpg

Overview of baseline characteristics of the groups and cohorts analyzed in the present study.

MS = Multiple Sclerosis; ALZ = Alemtuzumab; DMF = Dimethyl Fumarate; FTY = Fingolimod; GLAT = Glatiramer Acetate; IFN = beta Interferons; NAT = Natalizumab; TFM = Teriflunomide; f = female; m = male; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS; PPMS = primary progressive MS; NA = not applicable; unk = unknown.